Recruiting
Phase 2

Psilocybin

Sponsor:

Yvan Beaussant, MD, MSci

Code:

NCT06001749

Conditions

Opioid-Related Disorders

Pain Management

Pain Management and Care

Advanced Cancer

Advanced Cancers

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Psilocybin

Study Details

Brief summary:

The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer.

The name of the study intervention used in this research study is:

Psilocybin (a tryptamine derivative)

Conditions

Opioid-Related Disorders

Pain Management

Pain Management and Care

Advanced Cancer

Advanced Cancers

Study ID

NCT06001749

Start date

Sep 23, 2024

Status verified date

Aug, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Oct 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must be 18 year old or older;
  • Participants must have advanced cancer, defined as a cancer that is unlikely to be cured or controlled with treatment;
  • Participants must have progressed on or be intolerant to approved therapies with a known clinical benefit (unless it is documented that they have refused such treatments);
  • Participants must evaluate their average pain on BPI Severity Scale ≥ 4/10 over the past week;
  • Participants must receive chronic opioid pharmacotherapy for pain with an Oral Morphine Equivalent (OME) ≥ 200mg/day;
  • Participants must have been seen by a palliative care clinician either at DFCI, MGH or associated satellites in the last three months;
  • Participants must have an ECOG Performance Status ≤ 2
  • Participants must meet the following organ and marrow function on their last available bloodwork as defined below:

  • Platelets ≥ 50,000/mcL
  • AST(SGOT)/ALT(SGPT) ≤ 5 × institutional ULN
  • Participants must be able to understand and willing to sign a written informed consent document
  • Participants must be able to swallow pills.
  • Participants must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.
  • Participants must agree to inform the investigators within 48 hours of any new medical conditions and procedures.
  • Participants must agree to the following lifestyle modifications (described in more detail in Section 3.4 Lifestyle Modifications):

  • Comply with requirements for diet,
  • Refrain from certain medications prior to Experimental Sessions,
  • Be driven home after each Experimental Session,
  • Commit to medication dosing, therapy, and study procedures.

Exclusion Criteria:

  • Participants who receive concurrent (less than four weeks or planned within 6 weeks) cytotoxic chemotherapy or radiation therapy that may impair general level of physical functioning or affect study outcomes;
  • Participants with a condition impairing oral intake or digestive absorption;
  • Participants who are not able to give adequate informed consent;
  • Participants who have a significant suicide risk as defined by suicidal ideation with intent and with or without a plan as endorsed on items 4 and/or 5 on the C-SSRS within the past 6 months or at V0
  • Participants who have a history of, or a current diagnostic of primary psychotic disorder, major depressive disorder with psychotic features, bipolar affective disorder type 1 or history of or current dissociative identity disorder; and participants who have an ongoing substance use disorder (defined as active in the past year). Participants with first-degree relatives with schizophrenia or bipolar disorder may be eligible depending on their age and personal and family psychiatric history. The decision will be made by the principal investigator and study psychiatrist based on risk assessment.
  • Participants for whom there is a potential for adverse drug-drug interactions. Concomitant medications with significant potential to interact with study medications will be exclusionary if they cannot be tapered. These include the following:

  • Serotoninergic antidepressants
  • Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  • Tricyclic Antidepressants (TCAs)
  • Efavirenz
  • serotonin-acting dietary supplements (i.e. 5-hydroxy-tryptophan or St. John's wort)
  • Centrally-acting serotonergic agents (e.g. MAO inhibitors)
  • Antipsychotics (e.g. first and second generation)
  • Mood stabilizers (e.g. lithium, valproic acid)
  • Aldehyde dehydrogenase inhibitors (e.g. disulfiram)
  • Significant inhibitors of UGT 1A0 or UGT 1A10 Any psychiatric medication will be tapered if possible in an appropriate fashion to avoid withdrawal effects. They will be discontinued long enough before the psilocybin Session to avoid the possibility of any drug-drug interaction (the interval will be at least five times the particular drug and active metabolites' half-life + one week for stabilization). See section 5.3 of the protocol for concomitant medications and tapering instructions.
  • Participants who have evidence or history of significant (controlled or uncontrolled) hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration (participants with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded).
  • Participants with brain tumors or brain metastases that haven't been successfully treated
  • Participants with lab abnormalities that may contribute to somnolence, confusion or delayed metabolism of psilocybin and/or with severe lab abnormalities (grade 3 or more per CTCAE scale).
  • Participants with a diagnosis of cirrhosis or liver failure
  • Participants who have uncontrolled hypertension using the standard criteria of the American Heart Association (values of 140/90 milligrams of Mercury \[mmHg\] or higher assessed on three separate occasions)
  • Participants who have a heart rate > 100 bpm on three separate occasions
  • Participants who have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (PVCs) in the absence of ischemic heart disease.
  • Participants who have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation.
  • Participants who have a history of arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening. Participants with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia or any other arrhythmia associated with a bypass tract may be enrolled if they have been successfully treated.
  • Participants who have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Participants who have a history of myocardial infarction, coronary artery disease or heart failure
  • Participants who have a marked Baseline prolongation of QT/QTc interval. For purposes of eligibility, this is defined as repeated demonstration of a QT interval corrected on the triplicate ECGs performed at screening, using Fridericia's formula \[QTcF\] > 450 milliseconds \[ms\] in males and > 460 ms in females.
  • For transgender or non binary participants, QTc interval will be evaluated based on sex assigned at birth, unless the participant has been on hormonal treatment for five or more years.
  • Women who are pregnant, nursing, or able to become pregnant and are not practicing an effective means of birth control. Acceptable methods of contraception are the following: intrauterine device, injected/ implanted/ intravaginal/ transdermal hormonal method, oral hormones plus a barrier contraception, abstinence, vasectomized sole partner, or double barrier contraception.
  • Participants who have hypersensitivity to any ingredient of the IMP (Investigational Medicinal Product).

Study Design

Enrollment

15 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Psilocybin

Participants will complete study procedures as follows:

  • 2, in-clinic or remote, preparation sessions with therapists.
  • In-clinic treatment session with therapists at Dana-Farber Cancer Institute. Participants will take a predetermined amount of psilocybin once. Participants will be transported home by a friend or family member.
  • In-clinic integration session the day after psilocybin administration with therapists.
  • In-clinic or remote, integration session with therapists 1 week after psilocybin administration.
  • In-clinic or remote follow visits with therapists at week 2, 3, 5, 8, and 12 after psilocybin administration.

Interventions

Psilocybin

A tryptamine derivative, capsule, taken orally.

Primary outcome measure

  • Feasibility of Psilocybin-Assisted Therapy [ Time Frame: 3 weeks ]
  • Acceptability of Psilocybin-Assisted Therapy [ Time Frame: 3 weeks ]

Central Contacts and Locations

Central contacts

Amani Ingram

8572151476patresearch@dfci.harvard.edu

Isabel Kristan

6176322574patresearch@dfci.harvard.edu

Locations

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Isabel Kristan

857-215-1476patresearch@dfci.harvard.edu

Principal Investigator:

Yvan Beaussant, MD

More Information

Sponsor

Yvan Beaussant, MD, MSci

Last update posted

Aug 5, 2026

Last verified

Aug, 2026

Keywords

  • Opioid-Related Disorders
  • Pain Management
  • Pain Management and Care
  • Advanced Cancer
  • Advanced Cancers

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Yvan Beaussant, MD, MSci on 2026-08-05.